Search

Displaying results 1831 - 1840 of 5419 in total
  1. Drug

    Magaldrate

    go.drugbank.com/drugs/DB08938
    ApprovedInvestigationalWithdrawn

    Magaldrate has been discontinued in the US market.

  2. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market.

  3. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

  4. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    [A187496,L9521] The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation. … It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.

  5. Drug

    Procaterol

    go.drugbank.com/drugs/DB01366
    ApprovedWithdrawn

    It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

    Categories: Adrenergics for Systemic Use
  6. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]

  7. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is designed for intravenous administration for acute use … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  8. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.

  9. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    This large disadvantage was overcome with animal-derived surfactant products which contain specific proteins but are limited, but must be derived from animal sources. … Phase 3 clinical trials with Surfaxin show promising results with similar efficacy as animal-derived surfactants while avoiding the use of animal-origin products.

  10. Drug

    Nitrofural

    go.drugbank.com/drugs/DB00336
    ApprovedVet approvedWithdrawn

    Except for topical drug products formulated for dermatologic application, the FDA withdrew its approval for the use of drug products containing nitrofurazone.[L43942]